

**Bulletin from Annual General Meeting in Magle Chemoswed Holding AB (publ) held on
May 17, 2022.**

Today, on May 17, 2022, the annual general meeting was held in Magle Chemoswed Holding AB (publ) by way of advance voting (postal vote) in accordance with temporary legislation.

A summary of the adopted resolutions follows below:

- Adoption of the Income Statement and Balance Sheet

The AGM resolved, in accordance with the Board of Director's proposal, to adopt the income statement and the consolidated income statement, as well as the balance sheet and the consolidated balance sheet, as set out in the annual report 2021.

- Allocation of Profits

The AGM resolved, to appropriate of the company's results according to the Board's proposal in the annual report. The AGM also resolved, in accordance with the Board's proposal, that no dividend be paid for 2021.

- Discharge from Liability

The AGM resolved, in accordance with the Board's proposal supported by the auditor, to discharge the members of the Board of Directors and the CEO, respectively, from liability in respect of their management of the Company's business during the financial year 2021.

- Election of the Board Members, Auditor, Fees to the Directors and Auditor

The AGM resolved, in accordance with the proposal, that the number of Directors appointed by the general meeting shall remain the same, i.e. the Board of Directors shall consist of six (6) directors and one deputy director appointed by the general meeting. The AGM resolved in accordance with the proposal to re-elect Hans Henrik Lidgard, Martin Lidgard, Malin Malmsjö, Sven-Christer Nilsson, Mats Pettersson and Joel Eklund as ordinary members of the Board and to re-elect Julia Kamber as a deputy member of the Board. It was further resolved to re-elect Hans Henrik Lidgard as chairman of the Board of Directors. All elections are for the period until the end of the next annual general meeting.

It was resolved to elect Ernst & Young AB with authorized auditor Henrik Rosengren, as the auditor of the Company until the end of General Meeting 2023.

The AGM resolved in accordance with the proposal that remuneration for the Board Members appointed by the shareholders' meeting that are not employed by the group shall amount to 100 000 SEK and for the deputy member - 50 000 SEK for the time until the end of the next annual shareholders' meeting, whereof the chairman of the Board shall receive 200 000 SEK. The committee members shall receive 25 000 SEK.

The AGM resolved as proposed that the remuneration to the auditor shall be in accordance with the approved rates.

- Authorisation for the Board to issue new shares

The meeting resolved to authorise the Board to issue new shares, with or without pre-emption rights for the shareholders. The total number of shares that may be issued by virtue of the authorisation must be within the limits of the share capital according to the articles of association. The total number of shares that may be issued by virtue of the authorisation may not exceed 10 per cent (%) of the total number of the shares in the Company at the time when the Board first utilizes the authorisation.

For further information, please contact:

Justin Pierce, CEO

Phone: +46 (0)70 593 58 21

Email: Justin.Pierce@maglechemoswed.com

About us

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes two operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Learn more on <https://maglegroup.com/> and <https://maglechemoswed.com/> and <http://www.maglepharmacept.com/>

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

